市場調查報告書
商品編碼
1416345
KRAS 抑制劑市場報告:2030 年趨勢、預測和競爭分析KRAS Inhibitors Market Report: Trends, Forecast and Competitive Analysis to 2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
KRAS 抑制劑的趨勢和預測
預計2024年至2030年全球KRAS抑制劑市場將以32.5%的複合年成長率成長。該市場的主要驅動力是不同類型癌症中KRAS突變的盛行率不斷增加、正在進行的臨床試驗數量的快速增加以及對精準醫療和個人化癌症治療的投資的增加。全球KRAS抑制劑市場前景廣闊,臨床實驗室、癌症診斷中心、醫院、癌症研究機構和學術機構市場充滿機會。
KRAS抑制劑市場洞察
Lucintel 預測,由於肺癌患者 KRW 突變盛行率急劇上升,以及人們對肺癌治療研究的關注度增加,肺癌在預測期內將經歷最高成長。
由於臨床研究的增加以及研究機構和生物技術公司之間合作夥伴關係的擴大,癌症研究機構將繼續成為該市場的最大部分。
由於癌症發生率高且該地區有主要企業,北美在整個預測期內可能仍然是最大的地區。
Q1.市場成長預測是多少:
A1. 2024年至2030年,全球KRAS抑制劑市場預計將以32.5%的複合年成長率成長。
Q2. 影響市場成長的關鍵促進因素是:
A2. 該市場的主要驅動力是不同癌症類型中 KRAS 突變的流行、正在進行的臨床試驗數量的快速增加以及對精準醫療和個性化癌症治療的投資的增加。
Q3.市場的主要細分市場是:
A3. 全球KRAS抑制劑市場前景廣闊,臨床實驗室、癌症診斷中心、醫院、癌症研究機構和學術機構市場充滿機會。
Q4.市場的主要企業是:
A4. 一些主要的 KRAS 抑制劑公司是:
Q5.未來最大的細分市場是什麼?
A5.Lucintel 預測,由於肺癌患者中 KRW 突變的盛行率急劇上升,人們越來越關注肺癌治療方法的研究,肺癌將在預測期內經歷最高的成長。
Q6.未來五年預計哪些地區的市場成長最大?
答:由於癌症發生率高且主要企業在該地區的存在,北美在整個預測期內仍將是最大的地區。
Q7. 可以客製化報告嗎?
A6. 是的,Lucintel 提供 10% 的客製化服務,無需額外付費。
KRAS Inhibitors Trends and Forecast
The future of the global KRAS inhibitors market looks promising with opportunities in the clinic laboratory, cancer diagnostic center, hospital, cancer research institute, and academic institution markets. The global KRAS inhibitors market is expected to grow with a CAGR of 32.5% from 2024 to 2030. The major drivers for this market are increasing prevalence of KRAS mutations in various types of cancer, surge in number of ongoing clinical trials, and growing investments in precision medicine and personalized cancer treatment.
A more than 150-page report is developed to help in your business decisions.
KRAS Inhibitors by Segment
The study includes a forecast for the global KRAS inhibitors by cancer type, end use, and region.
KRAS Inhibitors Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:
KRAS Inhibitors Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
KRAS Inhibitors Market by Region [Shipment Analysis by Value from 2018 to 2030]:
List of KRAS Inhibitors Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies KRAS inhibitors companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the KRAS inhibitors companies profiled in this report include-
KRAS Inhibitors Market Insights
Lucintel forecasts that lung cancer is expected to witness highest growth over the forecast period due to surge in prevalence of KRW mutations in lung cancer patients and increasing focus towards research for lung cancer treatments.
Within this market, cancer research institutes will remain the largest segment due to the rising number of clinical research along with growing partnerships among research institutes and biotech companies.
North America will remain the largest region over the forecast period due to the high prevalence of cancer and presence of major players in the region.
Features of the Global KRAS Inhibitors Market
Market Size Estimates: KRAS inhibitors market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: KRAS inhibitors market size by cancer type, end use, and region in terms of value ($B).
Regional Analysis: KRAS inhibitors market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different cancer types, end uses, and regions for the KRAS inhibitors market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the KRAS inhibitors market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q1. What is the growth forecast for KRAS inhibitors market?
Answer: The global KRAS inhibitors market is expected to grow with a CAGR of 32.5% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the KRAS inhibitors market?
Answer: The major drivers for this market are increasing prevalence of KRAS mutations in various types of cancer, surge in number of ongoing clinical trials, and growing investments in precision medicine and personalized cancer treatment.
Q3. What are the major segments for KRAS inhibitors market?
Answer: The future of the global KRAS inhibitors market looks promising with opportunities in the clinic laboratory, cancer diagnostic center, hospital, cancer research institute, and academic institution markets.
Q4. Who are the key KRAS inhibitors market companies?
Answer: Some of the key KRAS inhibitors companies are as follows:
Q5. Which KRAS inhibitors market segment will be the largest in future?
Answer: Lucintel forecasts that lung cancer is expected to witness highest growth over the forecast period due to surge in prevalence of KRW mutations in lung cancer patients and increasing focus towards research for lung cancer treatments.
Q6. In KRAS inhibitors market, which region is expected to be the largest in next 5 years?
Answer:North America will remain the largest region over the forecast period due to the high prevalence of cancer and presence of major players in the region.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.